RTB, We don't have all the information to make
Post# of 148190
(Total Views: 506)
Posted On: 03/06/2021 1:13:54 PM
RTB,
We don't have all the information to make a good calculation. we are missing:
The exact split between SOC and VX
The total number of deaths.
We have some percentages. I choose those numbers because they conform with most of the percentages we were given, also, we need to take into account the last statement:
So, the number of deaths in SOC is larger rather than smaller. It would seem that 2-3 survivals in this arm is likely.
Also, if we take the AVERAGE discharged alive (28+11)/2=19.5% times 62 yields 12 patients discharged (around 50 deaths all together). That is why my "mortality" is larger
.
However, all of the above pure speculation, as you well point out, we are just "fitting" data to the percentages given.
We don't have all the information to make a good calculation. we are missing:
The exact split between SOC and VX
The total number of deaths.
We have some percentages. I choose those numbers because they conform with most of the percentages we were given, also, we need to take into account the last statement:
Quote:
Discharge alive: In addition, patients who received leronlimab demonstrated an improved probability of "discharged alive" at Day 28 (28% versus 11%), a 166% better rate than in the placebo group.
So, the number of deaths in SOC is larger rather than smaller. It would seem that 2-3 survivals in this arm is likely.
Also, if we take the AVERAGE discharged alive (28+11)/2=19.5% times 62 yields 12 patients discharged (around 50 deaths all together). That is why my "mortality" is larger
. However, all of the above pure speculation, as you well point out, we are just "fitting" data to the percentages given.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼